ACTH Medication-Driven Changes: What Every Lab Result Means

What Is the Normal and Optimal ACTH Range?

The conventional reference interval for a morning (08:00) plasma ACTH draw is 10 to 60 pg/mL (approximately 2.2 to 13.3 pmol/L), established across multiple large immunoradiometric assay validation studies [1]. Afternoon values are physiologically lower, often 5 to 30 pg/mL, because ACTH secretion follows a diurnal rhythm driven by the suprachiasmatic nucleus.

Why "Normal" and "Optimal" Differ

"Normal" describes the 2.5th, 97.5th percentile in a reference population, which includes people with subclinical HPA-axis dysfunction. Many longevity and functional-endocrinology clinicians prefer a tighter optimal window of 15 to 55 pg/mL at 08:00, aiming to confirm that both the pituitary and adrenal glands are responding correctly without stress-driven oversecretion.

Values below 5 pg/mL at 08:00, when paired with a low simultaneous cortisol (<10 mcg/dL), meet the biochemical threshold for secondary or tertiary adrenal insufficiency used in the 2016 Endocrine Society clinical practice guideline [2].

Assay Variability Matters

ACTH is notoriously unstable ex vivo. A 2018 analysis published in the Annals of Clinical Biochemistry showed that samples left at room temperature for 30 minutes lost up to 30% of immunoreactive ACTH [3]. Labs using different two-site immunochemiluminometric assay (ICMA) platforms report reference intervals that shift by as much as 15 to 20 pg/mL, so comparing results across institutions requires knowing the assay used.

Diurnal Rhythm and Sampling Protocol

Draw ACTH and cortisol simultaneously at 08:00 after a 30-minute rest, with the patient off acute stressors. A second draw at 16:00 can confirm the expected afternoon nadir (roughly 40 to 50% of morning value). Failure to see that fall suggests a flattened diurnal rhythm, which has been associated with worse metabolic outcomes in population studies [4].

How Glucocorticoids Suppress ACTH

Exogenous glucocorticoids are the most common drug class to alter ACTH readings. They act at two levels: the hypothalamus (reducing CRH secretion) and the anterior pituitary (directly inhibiting POMC transcription and ACTH release) [5].

Dose-Dependent Suppression

The degree of suppression tracks closely with glucocorticoid potency and duration of use:

• Dexamethasone 0.5 mg/day for 3 days suppresses morning ACTH to below 10 pg/mL in the majority of healthy individuals, forming the basis of the low-dose dexamethasone suppression test.
• Prednisone 5 to 7.5 mg/day for more than 3 weeks produces measurable HPA suppression in approximately 50% of patients, based on data from the 2017 European League Against Rheumatism (EULAR) task force review of glucocorticoid-induced adrenal insufficiency [6].
• Prednisone at doses of 20 mg/day or more for 4 or more weeks suppresses ACTH below the assay detection limit in up to 80% of patients [6].

Recovery Timeline

After stopping long-term glucocorticoids, ACTH recovery typically precedes cortisol recovery because the pituitary responds faster than the atrophied adrenal glands. A landmark NEJM paper by Schlaghecke et al. (N=74) showed that some patients required 9 to 12 months before the cortisol response to a 250 mcg cosyntropin stimulation test normalized [7]. Patients should not be assumed to have recovered HPA function based on a single ACTH value alone.

Inhaled and Topical Steroids

Inhaled corticosteroids (ICS) at high doses also suppress ACTH. A 2021 meta-analysis in the European Respiratory Journal covering 27 trials (N=2,783) found that fluticasone propionate at doses of 1,000 mcg/day or more was associated with measurable morning cortisol suppression (a proxy for ACTH suppression) in 15 to 30% of adults [8]. Topical steroids applied to large surface areas can produce similar effects, particularly under occlusion.

Drugs That Raise ACTH: Adrenal Enzyme Inhibitors

Several drugs lower cortisol synthesis by blocking adrenal steroidogenic enzymes. With cortisol falling, the negative feedback on the pituitary is lost, and ACTH rises sharply. This rise is the intended pharmacologic signal in diagnostic testing, and an unintended side effect in therapeutic use.

Metyrapone

Metyrapone blocks 11-beta-hydroxylase (CYP11B1), the final step in cortisol synthesis. In an intact HPA axis, a single oral dose of 750 mg every 4 hours for 6 doses raises ACTH 2 to 4-fold above baseline within 4 to 6 hours [9]. The Endocrine Society's 2008 guideline on Cushing's syndrome lists the metyrapone test as one of three acceptable second-line confirmation tests, with ACTH rising above 75 pg/mL as a positive response in most protocols [10].

Therapeutically, patients treated with metyrapone for Cushing's disease (e.g., at 500 to 4,000 mg/day in divided doses) show persistently elevated ACTH. Clinicians must monitor for cortisol escape and watch for ACTH-driven androgenic side effects, including acne and hirsutism from adrenal androgen overproduction.

Ketoconazole

Ketoconazole inhibits multiple cytochrome P450 enzymes in the adrenal cortex, including CYP17A1 and CYP11A1, reducing both cortisol and androgen synthesis. At therapeutic doses of 200 to 400 mg twice daily, ACTH rises as cortisol falls. A 2014 case series in the Journal of Clinical Endocrinology and Metabolism (N=38) documented mean ACTH increases of 45% above pretreatment values within 4 weeks of starting ketoconazole at these doses [11]. Monitoring ACTH every 4 to 6 weeks during dose titration prevents cortisol deficiency while ensuring adequate cortisol suppression.

Osilodrostat and Levoketoconazole

Osilodrostat (Isturisa), FDA-approved in 2020 for Cushing's disease, inhibits CYP11B1 and CYP11B2. The LINC 3 trial (N=137) demonstrated mean ACTH increases of approximately 2.4-fold from baseline at 48 weeks, a consistent pharmacological finding [12]. Levoketoconazole (Recorlev), approved by the FDA in December 2021 for endogenous Cushing's syndrome, produces similar ACTH elevation through the same mechanism [13].

Mifepristone and Glucocorticoid Receptor Blockade

Mifepristone (Korlym) is a glucocorticoid receptor antagonist approved by the FDA in 2012 for hyperglycemia secondary to endogenous Cushing's syndrome [14]. Its mechanism creates a unique lab picture: cortisol levels rise (because the pituitary loses negative feedback from cortisol acting on its own receptor), and ACTH rises in parallel.

The Mifepristone Lab Paradox

Patients on mifepristone will show both high ACTH and high cortisol simultaneously. This pattern looks like primary hypercortisolism on paper but is entirely drug-driven. The SEISMIC trial (N=50) found mean ACTH values of 87 pg/mL at 24 weeks in patients on mifepristone 300 to 1,200 mg/day, compared to 38 pg/mL at baseline [15]. Cortisol-based monitoring is unreliable in these patients; clinical signs and urinary free cortisol are not interpretable either. Monitoring must rely on blood glucose, blood pressure, and clinical Cushing's features.

Dosing and Monitoring

The approved dose range for mifepristone in Cushing's syndrome is 300 to 1,200 mg/day. Adrenal insufficiency from over-blockade is a risk; the FDA label recommends stopping the drug and administering dexamethasone 0.5 to 1 mg (which bypasses the blocked receptor at low doses and competes for receptor occupancy at higher cortisol ratios) if adrenal crisis is suspected [14].

Other Drug Classes That Alter ACTH

Etomidate

Etomidate, an intravenous anesthetic, inhibits CYP11B1 at sub-anesthetic doses. A single induction dose of 0.3 mg/kg suppresses cortisol for 4 to 8 hours and transiently suppresses the adrenal response to ACTH. A 2012 meta-analysis in Critical Care Medicine (17 studies, N=1,896) found that a single etomidate dose in septic patients was associated with a statistically significant reduction in cortisol response to 250 mcg cosyntropin (mean delta cortisol 13.1 vs. 19.4 mcg/dL, P<0.001) [16]. ACTH itself rises transiently as cortisol falls but then normalizes within 12 to 24 hours.

Mitotane

Mitotane (Lysodren) is used in adrenocortical carcinoma. It destroys adrenocortical cells (both adenoma and normal tissue), producing primary adrenal insufficiency with dramatically elevated ACTH, often above 200 pg/mL. Patients require mineralocorticoid and glucocorticoid replacement. ACTH serves as a treatment-response marker: falling ACTH after dose adjustment suggests residual cortical function; persistently high values confirm adequate cytotoxic effect [17].

Pasireotide

Pasireotide (Signifor), a somatostatin analogue approved for Cushing's disease in 2012, binds somatostatin receptor subtype 5 (sst5) on corticotroph cells, directly suppressing ACTH secretion at the pituitary level. The PASPORT-CUSHINGS trial (N=162) showed that pasireotide 600 or 900 mcg twice daily reduced 24-hour urinary free cortisol in 26 to 35% of patients and reduced ACTH to below the upper limit of normal in a subset of responders [18].

Cabergoline

Cabergoline, a dopamine D2 agonist used primarily for hyperprolactinemia, suppresses ACTH in some patients with Cushing's disease through D2 receptor expression on corticotroph tumors. Response rates vary widely; a systematic review in the European Journal of Endocrinology (2015, 15 studies, N=200) found ACTH normalization in only 25 to 40% of treated patients [19]. Cabergoline is not a first-line agent for Cushing's, but its effect on ACTH should be noted when interpreting labs in patients receiving it for prolactinoma.

Antidepressants and Psychiatric Medications

Chronic SSRI use appears to modestly reduce basal HPA-axis activity. A 2020 meta-analysis in Psychoneuroendocrinology (N=3,214, 22 studies) found that SSRIs reduced the cortisol awakening response by a mean of 0.12 standard deviations compared to placebo [20]. ACTH effects were less consistently reported but trended in the same direction. This effect is unlikely to push ACTH outside the reference range but may confound borderline values near the lower limit of normal.

ACTH in Primary vs. Secondary Adrenal Insufficiency: The Drug-Induced Distinction

The central clinical use of ACTH is differentiating primary from secondary adrenal insufficiency. Drugs complicate this separation substantially.

Primary Adrenal Insufficiency (Addison's Disease)

In primary adrenal insufficiency, the adrenal glands fail to produce cortisol. The pituitary responds with sustained high ACTH output, typically above 100 pg/mL and sometimes above 500 pg/mL. The Endocrine Society's 2016 clinical practice guideline states: "A morning plasma ACTH concentration clearly above the upper limit of normal (generally above 2 times the upper reference limit) supports a diagnosis of primary adrenal insufficiency in the presence of low cortisol" [2].

Drug-induced primary adrenal insufficiency can occur with mitotane, aminoglutethimide, and bilateral adrenal destruction from heparin-induced thrombocytopenia. In these cases, ACTH rises identically to autoimmune Addison's disease.

Secondary Adrenal Insufficiency

Secondary adrenal insufficiency from drugs, almost always exogenous glucocorticoid suppression, presents as low ACTH with low cortisol. The pituitary is suppressed, not the adrenal glands. This is the biochemical opposite of primary disease. A morning ACTH below 10 pg/mL with a concurrent morning cortisol below 5 mcg/dL, in a patient with a history of glucocorticoid use for 3 or more weeks, is diagnostic of drug-induced secondary adrenal insufficiency without further testing in most clinical guidelines [2].

The cosyntropin (Cortrosyn) stimulation test using 250 mcg IV remains the gold standard for confirming adrenal reserve. A peak cortisol below 18 mcg/dL at 30 or 60 minutes confirms insufficient adrenal reserve [2]. A low ACTH alone is not sufficient to cancel a cosyntropin test, because the adrenal glands may still respond normally after mild or brief pituitary suppression.

A Clinical Decision Framework for Drug-Altered ACTH

When a patient's ACTH result is unexpected, the following three-step sequence organizes the workup:

1. Confirm the sample. Was the draw at 08:00, on ice, centrifuged within 15 minutes? Re-draw if not.
2. List every drug. Include inhaled, topical, and herbal preparations. Licorice root elevates cortisol by inhibiting 11-beta-hydroxysteroid dehydrogenase type 2, which secondarily suppresses ACTH.
3. Pair ACTH with simultaneous cortisol. High ACTH plus low cortisol = primary insufficiency or enzyme inhibitor effect. Low ACTH plus low cortisol = glucocorticoid suppression. High ACTH plus high cortisol = mifepristone effect or ectopic ACTH. Low ACTH plus high cortisol = autonomous cortisol-secreting adrenal adenoma.

Monitoring ACTH During Hormone Therapy and TRT

Testosterone replacement therapy (TRT) and estrogen-based hormone therapy do not directly suppress ACTH, but both alter cortisol-binding globulin (CBG), which changes total cortisol readings without necessarily changing free cortisol or ACTH. This can create apparent discordance between ACTH and total cortisol results.

Oral Estrogens and CBG

Oral estradiol raises CBG substantially, increasing total cortisol values while free cortisol remains stable. A 2016 study in the Journal of Clinical Endocrinology and Metabolism (N=112) found that oral contraceptive pill users had total cortisol concentrations 50 to 100% above non-users at the same ACTH and free cortisol levels [21]. Transdermal estradiol does not raise CBG to the same degree, making it the preferred route when serial cortisol monitoring is planned.

Testosterone and Cortisol Interactions

Supraphysiologic testosterone doses, such as those used in some off-label TRT protocols above 200 mg/week, have been associated in small pharmacokinetic studies with modest reductions in the cortisol stress response through androgen-receptor-mediated attenuation of CRH secretion. ACTH values at standard TRT doses (100 to 200 mg/week testosterone cypionate) are not consistently changed from baseline in published pharmacokinetic data. Clinicians ordering ACTH in TRT patients should interpret the result primarily on the basis of any concurrent glucocorticoid or adrenal-modifying drugs.

Specimen Collection and Pre-Analytical Variables

Getting an accurate ACTH result depends as much on collection technique as on the underlying biology.

Collection Protocol

• Use a pre-chilled EDTA (purple-top) tube.
• Draw at 08:00 after 30 minutes of rest in the supine position.
• Transport on ice to the lab immediately.
• Centrifuge at 4°C within 15 minutes of collection.
• Freeze plasma at minus 20°C or colder if not assayed within 2 hours [3].

Interference Sources

Biotin supplementation at doses above 5 mg/day can interfere with streptavidin-biotin immunoassay platforms, falsely lowering ACTH readings. The FDA issued a safety communication on biotin interference in 2019, noting that doses as low as 10 mg/day had produced clinically significant assay errors [22]. Patients should stop biotin supplementation 72 hours before ACTH testing.

Heterophilic antibodies, present in roughly 0.5% of the general population, can spuriously raise ACTH on two-site immunoassay platforms. If the clinical picture does not match the lab value, requesting a repeat with a different assay platform or after heterophilic antibody blocking reagents is reasonable.